Chemomab Therapeutics has announced that it has successfully completed its End-of-Phase 2 meeting with the FDA, aligning on the design of a single Phase 3 trial for its lead product candidate, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback